Page 2,850«..1020..2,8492,8502,8512,852..2,8602,870..»

Is 'in vitro meat' moving closer to the menu?

Posted: February 23, 2012 at 8:45 am

VANCOUVER, British Columbia

In a laboratory in the Netherlands, stem cells from cows are being grown into what researcher Mark J. Post says will be the first so-called "test-tube burger" -- comprising the tiny pieces of tissue-engineered, or "in vitro," meat -- that he and his colleagues aim to cook and taste as early as this October.

By this summer, California researcher Patrick O. Brown says, a company he's helped start will bring to market a revolutionary new plant-based substitute for a meat or dairy food -- he's not yet sharing specifics -- that "can't be distinguished from the animal product it replaces, even by hard-core foodies."

The scientists are on the leading edge of a movement to dramatically change how the world grows and consumes meat, something they say must happen, one way or another.

"Animal farming is by far the biggest ongoing global environmental catastrophe," Mr. Brown said Sunday at a news briefing for journalists from around the world at the annual meeting of the American Association for the Advancement of Science, attended by some 5,000 delegates and 700 media people in Vancouver.

He and Mr. Post were part of a panel of four experts who later that day presented a symposium titled, "Meat without Animals: Test-tube Burgers and More." It was provocative enough that the Times of London broke a news embargo to publish something on it that morning, and bits of the story have been broadcast this week as far and wide as the local TV news in Pittsburgh.

The issue certainly is food for thought.

Mr. Brown, a biochemist at the Stanford University School of Medicine, wants to see a world without animal farming, because "in every conceivable way, it's inefficient and destructive."

Inefficient, in that it takes many pounds of grains, and many, many gallons of water, to make a typical quarter-pounder. Destructive, he said, citing sobering United Nations statistics, that show animal farming takes up about 30 percent of the Earth's land, accounts for more than 18 percent of greenhouse gas emissions, is the largest source of water pollution and the biggest threat to biodiversity.

Meanwhile, the world's appetite for meat is expected to double by 2050.

Mr. Brown called animal agriculture, mostly unchanged for centuries, as "a sitting duck for a disruptive technology."

That's why, with backing from a Silicone Valley venture capital firm, he's launched two startups to create and market alternative foods that, like him, are vegetarian.

Of course, the market already has plenty of meat substitutes and non-dairy "cheeses," but he says they're not very good and they're expensive, and they're marketed to people who've already chosen to be vegetarian or vegan for health or ethical reasons, not to the mainstream.

The products he plans will compete head-on with animal products by being "high-value, protein-rich, nutrient-dense human foods that appeal to consumers" -- stand-ins for everything from bacon to cheddar.

Professor Post of Maastricht University said that he hopes Mr. Brown and others are able to fix the problems of animal agriculture with plants. But because he believes many people want real meat, his research is about producing that in a more efficient, less environmentally degrading way.

Cows are only about 15 percent efficient at making meat from grains and other foods, he said. Making beef under more controlled conditions could feed a lot more people while using fewer resources, saving the grains for human consumption as food as well as biofuel. (Their aim is to grow meat with vegetable-based nutrients, perhaps involving algae.)

With backing of $330,000 from a "reputable," non-food-industry funder he's not yet identifying, his team is working to grow enough muscle cells to show that "cultured meat" is possible.

Already, they've grown bovine stem cells into tiny strips about an inch long and 2/100ths of an inch thick.

They'll need thousands of these to make a burger (the golf-ball-sized goal sounds more like a slider, and an expensive one at that). But that's just one of many challenges.

Growing stem cells happens in labs all over the world, including Pittsburgh, where some researchers envision being able to make replacement organs for humans.

Bits for ground beef, the most popular meat in the U.S., look to be relatively easy. (Mr. Post got laughs when recounting how they started with pig cells, planning to make sausage, which can be "hardly recognizable as a meat product" anyway).

But muscle cells on an animal grow because of conditions that scientists have to figure out how to create in the petri dish. Mr. Post described using electric current to "exercise" the cow muscle cells, and treatments ranging from administering caffeine to withholding light to get them to make more myoglobin, which gives meat its red color.

"Right now, it's sort of a pinkish-yellowish," he told journalists. "The color is an interesting issue."

But, as he said later, it's also a scientifically controllable one. His part of the talk touched on possibilities including lowering the saturated fat and cholesterol of various meats, even creating custom combinations of meats.

His Powerpoint presentation illustrated the ultimate goal -- making "big slabs of meat" -- which were fancifully depicted as octagonal steaks, on round ceramic "bones."

Even if he does taste that burger this fall, cultured filet mignons are a long ways off. They will be expensive, as will all the research it'll take.

"But what's the cost of traditional meat production?" asked Nicholas Genovese, a visiting scholar at the University of Missouri-Columbia who organized the symposium. He includes in that the costs of dealing with outbreaks of food-borne illness and other human health woes associated with animal foods.

One of the issues he stresses is the ethical one of millions of animals being killed. His research, in fact, is funded by a grant from the People for the Ethical Treatment of Animals, which in 2008 offered a $1 million reward for the first researchers to make in vitro chicken meat, indistinguishable from the "real" deal, and sell it to the public by June 30, 2012.

That offer stands and might be extended at a PETA meeting in Los Angeles in April, PETA President Ingrid Newkirk said in a phone interview from Washington, D.C., last week. "Originally, we thought we'd never have to pay out," she said. "Nobody had heard of [in vitro meat]. We wanted to boot it into the public consciousness."

Now, she says, "We're feeling very good" about the research progress that's been made. "If this allows them to get rid of cruelty to animals, fabulous."

She's well aware that the idea of in vitro meat can stir strong reactions from everyone from Midwest farmers to home cooks, but says, "Everybody fears change," and points out that many foods such as soy milk were once little known.

The AAAS panelists included KeShun Liu, a U.S. Department of Agriculture researcher who talked about the next generation of extruded meat "analogs" that mimic the fibers of real chicken and turkey. (He said to look for products soon from Maryland's Savage River Farms).

The panelists agreed they're not advocating for legislation or subsidies; they're just working for alternatives for consumers.

Some acceptance of these new alternatives may be a matter of language. At the AAAS meeting, Mr. Genovese stressed, "In vitro meat will never be produced in the 'lab.' " As beer is made in a brewery, he has proposed calling meat production facilities of the future "carneries."

Bob Batz Jr.: bbatz@post-gazette.com or 412-263-1930.

First published on February 23, 2012 at 12:00 am

Read more:
Is 'in vitro meat' moving closer to the menu?

Posted in Stem Cell Videos | Comments Off on Is 'in vitro meat' moving closer to the menu?

Monkeys' Parkinson's woes eased via stem cells

Posted: February 23, 2012 at 8:45 am

Thursday, Feb. 23, 2012

KYOTO — Researchers have succeeded in improving the treatment of Parkinson's disease by using human embryonic stem cells to create nerve cells that produce dopamine and then transplanting the cells into monkeys' brains.

Four monkeys with Parkinson's disease — and previously unable to walk due to their symptoms — improved substantially after the human nerve cells were transplanted into their brains, reducing the shaking in their limbs and leading to some regaining the ability to walk, the research team, including Kyoto University professor Jun Takahashi, said Tuesday.

It is the first time pluripotent human embryonic stem cells have been successfully transplanted to improve symptoms of Parkinson's disease in monkeys, according to the team.

Parkinson's disease is linked to drops in the production of dopamine — a neurotransmitter in the brain. While there are drugs to treat the progressive neurological illness, there is currently no treatment to stop dopamine levels from falling.

In the study, the researchers transplanted nerve cells derived from the human stem cells into the four monkeys' brains. About three months later, all of them began to show improvements in their symptoms and tests conducted a year after the operation confirmed the nerve cells had been successfully grafted in their brains.

The finding holds much promise for the future treatment of Parkinson's disease in humans using regenerative medicine, but the researchers cautioned that a lot more work lies ahead as the study also showed that transplanted nerve cells that were not appropriately matured led to the development of tumors, although they were not malignant and could be treated.

Read more here:
Monkeys' Parkinson's woes eased via stem cells

Posted in Stem Cell Videos | Comments Off on Monkeys' Parkinson's woes eased via stem cells

Nasal Stem Cells Show Promise in Repairing Spinal Cord Damage Caused by Contusion

Posted: February 23, 2012 at 8:45 am

An important new study by a team of scientists at RhinoCyte™ Inc., Louisville, Ky., details promising results on the effectiveness of olfactory (nasal) stem cells in repairing spinal cord damage resulting from the most common cause of these injuries — contusions (bruising) due to major trauma such as is seen in auto accidents, falls or combat. This could have major implication for the estimated 5 million people worldwide affected by spinal cord injuries – 1.275 million of them in the United States alone, where the cost of treatment exceeds $40.5 billion each year.

Louisville, Kentucky (PRWEB) February 22, 2012

An important new study released by a team of scientists at RhinoCyte™ Inc., Louisville, Ky., details promising results on the effectiveness of olfactory (nasal) stem cells in repairing spinal cord damage resulting from the most common cause of these injuries — contusions (bruising) due to major trauma. Their study is featured in the current issue of the Journal of Neurodegeneration and Regeneration.

The study, led by Dr. Fred Roisen, has great implication for the estimated 5 million people worldwide affected by spinal cord injuries – 1.275 million of them in the United States alone, where the cost of treatment exceeds $40.5 billion each year. Current treatment options are limited to retaining and retraining mobility; no drug therapies are available, but studies pertaining to stem cell treatments are showing great promise for these as well as other neurodegenerative conditions.

A previous study by the group made national headlines when lab rats whose spinal cords had been partially cut in the region of the animal’s neck in a way that disabled their front right paws were able to regain significant use of their paws after being injected with olfactory stem cells. The investigative team took the cells from the olfactory neurosensory epithelium — the part of the nose that controls the sense of smell — in adult volunteer donors who were already undergoing elective sinus surgery. The removal of the stem cells has no effect on the patients’ ability to smell. Also, the minimally invasive surgery is frequently done on an outpatient basis so the cells are readily available and, as such, are a potentially promising source of therapeutic stem cells.

The researchers isolated the stem cells and increased their numbers in the laboratory by growing them in an enriched solution. The cells were then injected into a group of lab rats. Twelve weeks later, these animals had regained control of their affected paws while a control group that received no cells had not.

This latest study continued that original work, by concentrating on contusions caused by blunt force trauma such as that resulting from an automobile accident or a fall. Spinal cord and head trauma are common among soldiers suffering serious combat injuries, too.

Two independent sets of experiments were conducted, beginning two weeks after the rats had received contusions administered in a computer-controlled surgery. In the first group, 27 out of 41 rats were injected with olfactory stem cells, while the remainder received none. In the second group, 16 rats were treated with olfactory stem cells, 11 received no treatment and 10 received stem cells grown from human skin to see how the olfactory cells compared with another stem cell source.

The results once again showed great promise, with 40 percent of the rats treated with the olfactory-derived stem cells showing significant improvement after just six weeks, compared to 30 percent of those treated with human skin-derived cells and only 9 percent of those receiving no treatment. In addition, the olfactory stem cell-treated rats showing the highest rate of improvement recovered much faster than the other groups.

“This is very exciting on numerous levels,” said Dr. Roisen. “As an autologous cell source — that is, the patient is both the donor and the recipient — olfactory stem cells bypass the time a patient must wait while a suitable donor is found, which can be critical to the outcome of the patient’s treatment. They also eliminate the need for immunosuppressive drugs, which have numerous negative side effects.

“And just as importantly, stem cells taken from the nose of an adult do away with the ethical concerns associated with using embryonic stem cells.”

The researchers are in the final stages of their enabling studies, which are scheduled to be completed by summer; Phase 1 safety studies could begin as soon as early next year.

Dr. Roisen is chief science officer and co-founder of RhinoCtye™, and a professor and chair of the University of Louisville School of Medicine’s Department of Anatomical Sciences and Neurobiology. The original work forming the basis for the contusion study was conducted by Dr. Roisen’s group at UofL and has been licensed to RhinoCtye™ (http://www.rhinocyte.com), a company he co-founded in 2005 with Dr. Chengliang Lu and Dr. Kathleen Klueber to develop and commercialize diagnostic tools and therapies for stem cell treatment of multiple degenerative and traumatic neurological diseases. RhinoCyte™ currently has three patents for olfactory stem cell treatments approved in the United States, Australia and Israel, with others pending worldwide.

###

Laurel Harper
Laurel92@msn.com
502-550-0089
Email Information

Excerpt from:
Nasal Stem Cells Show Promise in Repairing Spinal Cord Damage Caused by Contusion

Posted in Stem Cell Videos | Comments Off on Nasal Stem Cells Show Promise in Repairing Spinal Cord Damage Caused by Contusion

Japanese researchers find stem cells reduce monkeys' Parkinson's symptoms

Posted: February 23, 2012 at 8:45 am

Japanese researchers have been able to improve the symptoms of Parkinson's disease in monkeys by transplanting nerve cells derived from embryonic stem cells into their brains, the team has announced.

The finding is the world's first reported success of its kind with a primate, according to the research team led by associate professor Jun Takahashi of Kyoto University's Institute for Frontier Medical Sciences. It has been released in the online edition of US journal Stem Cells.

After the transplant, the monkeys, which had been almost unable to move, showed improvements in their symptoms to the point where they became able to walk on their own, the team said.

Parkinson's disease is a neurological illness believed to be caused by a deficit of the neurotransmitter dopamine in the brain.

Embryonic stem cells, which have the potential to become almost any type of tissue, are harvested from inside a blastocyst, which develops from a mammalian egg cell about a week after it is fertilised.

Takahashi's research team used the embryonic stem cells to cultivate a cell mass in which 35 per cent of the cells were dopamine-producing neurons.

These neurons then were transplanted into the four crab-eating monkeys, whose conditions were observed over a one-year period.

According to the study, the monkeys exhibited reduced shaking of their limbs half a year later. They had remained nearly motionless inside their cages all day long before the transplant, but the improvement of their symptoms eventually enabled them to occasionally walk around the cages.

The research team confirmed that normal nerve cells had been created in their brains.

The finding could mark a major breakthrough for applying embryonic stem cells in clinical settings, experts said. The Health, Labour and Welfare Ministry has been encouraging researchers to study the clinical applications of not only stem cells, but also induced pluripotent stem cells, which also can grow into many kinds of human cells.

Takahashi's team has already performed experiments to transplant iPS cells into monkeys' brains.

"We'll make further efforts to enhance the safety of these cell transplants," Takahashi said. "And we hope to start clinical application studies as early as three years from now."

More here:
Japanese researchers find stem cells reduce monkeys' Parkinson's symptoms

Posted in Stem Cell Videos | Comments Off on Japanese researchers find stem cells reduce monkeys' Parkinson's symptoms

Stem cell implants boost monkeys with Parkinson's

Posted: February 23, 2012 at 8:44 am

Monkeys suffering from Parkinson's disease show a marked improvement when human embryonic stem cells are implanted in their brains, in what a Japanese researcher said Wednesday was a world first.

A team of scientists transplanted the stem cells into four primates that were suffering from the debilitating disease.

The monkeys all had violent shaking in their limbs -- a classic symptom of Parkinson's disease -- and were unable to control their bodies, but began to show improvements in their motor control after about three months, Kyoto University associate professor Jun Takahashi told AFP.

About six months after the transplant, the creatures were able to walk around their cages, he said.

"Clear improvements were confirmed in their movement," he said.

Parkinson's disease is a progressive neurological illness linked to a decrease in dopamine production in the brain. There is currently no medical solution to this drop off in a key neurotransmitter.

The condition, which generally affects older people, gained wider public recognition when Hollywood actor Michael J. Fox revealed he was a sufferer.

Takahashi said at the time of the implant about 35 percent of the stem cells had already grown into dopamine neuron cells, with around 10 percent still alive after a year.

He said he wants to improve the effectiveness of the treatment by increasing the survival rate of dopamine neuron cells to 70 percent.

"The challenge before applying it to a clinical study is to raise the number of dopamine neuron cells and to prevent the development of tumours," he said.

"I would like to make this operation more effective and safe" before clinical trials, Takahashi said.

Takahashi said so far he had used embryonic stem cells, which are harvested from foetuses, but would likely switch to so-called Induced Pluripotent Stem (iPS) cells, which are created from human skin, for the clinical trial.

His team, which has also transplanted iPS cells into monkeys, are now looking to see if the primates with Parkinson's disease show similar improvements in their motor control.

Scientists say the use of human embryonic stem cells as a treatment for cancer and other diseases holds great promise, but the process has drawn fire from religious conservatives, among others.

Opponents say harvesting the cells, which have the potential to become any cell in the human body, is unethical because it involves the destruction of an embryo.

The Japanese government currently has no guidelines on the use of human stem cells in clinical research.

In October last year, the Court of Justice of the European Union banned the patenting of stem cells when their extraction causes the destruction of a human embryo, a ruling that could have repercussions on medical research.

Scientists warned that the ruling would damage stem cell research in Europe, while the Catholic church hailed it as a victory for the protection of human life.

The rest is here:
Stem cell implants boost monkeys with Parkinson's

Posted in Stem Cell Research | Comments Off on Stem cell implants boost monkeys with Parkinson's

Surgeons Urge Caution: Stem Cell Treatments Untested in Aesthetic Surgery

Posted: February 23, 2012 at 8:44 am

Dallas, TX (PRWEB) February 22, 2012

There is little evidence to support the safety and effectiveness of procedures, equipment and treatments that have been advertised using adult stem cells for aesthetic reconstruction, including plastic surgery and facial rejuvenation, according to physicians writing in Plastic and Reconstructive Surgery.

Dr. Rod J. Rohrich, chairman of the Department of Plastic Surgery at UT Southwestern Medical Center and editor-in-chief of the journal, published a position statement on “stem cell facelifts” and “stem cell breast augmentation,” also known as “natural breast augmentation.” Dr. Felmont F. Eaves III of Chapel Hill, N.C., and Dr. Phillip C. Haeck of Seattle, Wash.,collaborated on the statement on behalf of the American Society for Aesthetic Plastic Surgery (ASAPS) and the American Society of Plastic Surgeons (ASPS).

“There are encouraging data from studies in laboratories to suggest that the use of adult stem cells is a very promising field and may produce beneficial medical therapies to treat a variety of diseases,” the doctors said in the statement. They emphasized that there is a lack of consistency in the way stem cell facelift procedures are performed, and pointed out that many procedures are being advertised by physicians who are not board-certified for this type of treatment, and devices being sold for aesthetic stem cell treatments have not been approved for human use in the U.S.

In the report, the doctors encourage their peers to continue reporting clinic results and experimental research to peer-reviewed plastic surgery journals to both promote good science and to foster safety and best practices for stem cell use in aesthetic procedures. “Much more research needs to be conducted before any definitive statements can be made,” the report said. “[Until then,] stem cell based procedures should be performed in compliance with FDA regulatory guidelines.”

Dr. Rohrich said many of the advertisements claiming stem cells can aid in restoring facial and body youthfulness come from outside the U.S. “Further direct, approved clinical research is needed to validate those claims,” he said, “but the future is potentially bright for the use of adult stem cells in both plastic surgery and facial rejuvenation, as well as in medical procedures, such as restoring nerve and brain damage resulting from trauma or cancer, as well as reversing the severe effects of auto immune disease.”

To read the complete joint ASAPS/ASPS position statement on stem cell use in aesthetic surgery, including stem cell facelifts and natural breast augmentation, visit the ASPS, at their website.

About Rod J. Rohrich, M.D., F.A.C.S.
Dr. Rod J. Rohrich holds the Betty and Warren Woodward Chair in Plastic and Reconstructive Surgery at UT Southwestern Medical Center in Dallas, Texas. He also holds the UT Southwestern Medical Center Crystal Charity Ball Distinguished Chair in Plastic Surgery. He is a graduate of the Baylor College of Medicine with high honors, with residencies at the University of Michigan Medical Center and fellowships at the Massachusetts General Hospital/Harvard (hand/microsurgery) and Oxford University (pediatric plastic surgery). He has served as president of the American Society of Plastic Surgeons. He repeatedly has been selected by his peers as one of America's best doctors, and twice has received one of his profession's highest honors, the Plastic Surgery Educational Foundation Distinguished Service Award, which recognizes his contributions to education in his field. Dr. Rohrich participates in and has led numerous associations and councils for the advancement of plastic and reconstructive surgery. He is a native of North Dakota. He is married to Dr. Diane Gibby, also a plastic surgeon. They live in Texas with their two children.

###


More:
Surgeons Urge Caution: Stem Cell Treatments Untested in Aesthetic Surgery

Posted in Stem Cell Research | Comments Off on Surgeons Urge Caution: Stem Cell Treatments Untested in Aesthetic Surgery

Cancer Stem Cell Research Drives Growth in RBCC’s Target Market

Posted: February 23, 2012 at 8:44 am

NOKOMIS, Fla.--(BUSINESS WIRE)--

Research into Cancer Stem Cells (CSC) is on the rise, fueling industry growth that Rainbow Coral Corp. (OTCBB: RBCC.OB - News) expects to translate into demand for n3D cell growth technologies.

RBCC is finalizing an equity funding agreement with n3D Biosciences, the maker of a revolutionary new system that allows scientists to grow three-dimensional cell cultures more easily than ever before. The device, called the Bio-Assembler, could have an extraordinary impact on cell research worldwide, and RBCC expects to find a strong market for the device once its funding agreement with n3D is finalized.

Many cancers, including breast, prostate, pancreatic, colon, brain, and lung cancers, contain a subset of stem-like cells understood to play a critical role in the development and progression of the disease. Research suggests that these cells, called Cancer Stem Cells, are able to “seed” new tumor formation and drive metastasis.

Because these cells are believed to be at the root of the development and spread of cancer, they’re quickly becoming the center of cancer diagnostics and biomarkers. CSCs are resistant to a number of chemotherapy drugs and radiotherapy, and approximately 20 different strategies are currently being pursued in the hope of selectively targeting CSCs. This creates a huge opening for new companies and technologies dedicated to streamlining cellular research.

RBCC believes that the Bio-Assembler could allow researchers to dramatically shorten the development timeline for new CSC drugs and treatments, potentially proving very lucrative to the company.

For more information on Rainbow BioSciences, please visit http://www.rainbowbiosciences.com/investors.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Celgene Corp. (NASDAQ: CELG), Cardinal Health, Inc. (NYSE: CAH), Abbott Laboratories (NYSE: ABT) and Affymax, Inc. (NASDAQ: AFFY).

Follow us on Twitter at www.twitter.com/RBCCinfo.

About Rainbow BioSciences

Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.rainbowbiosciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

See the article here:
Cancer Stem Cell Research Drives Growth in RBCC’s Target Market

Posted in Stem Cell Research | Comments Off on Cancer Stem Cell Research Drives Growth in RBCC’s Target Market

Buzz:Test tube beef – Video

Posted: February 22, 2012 at 7:51 pm

21-02-2012 05:39 (WTNH)-- Would you be willing to eat a burger that was grown in a test tube? Researchers say they have come up with a way to grow meat in a lab using animal stem cells.

Here is the original post:
Buzz:Test tube beef - Video

Posted in Stem Cells | Comments Off on Buzz:Test tube beef – Video

Carrboro man to get stem cell transplant

Posted: February 22, 2012 at 7:51 pm

Published: Feb 22, 2012 02:00 AM
Modified: Feb 20, 2012 10:41 PM


Carrboro man to get stem cell transplant
Treatment a first at UNC

BY ELIZABETH SWARINGEN, Special to The Chapel Hill News

CHAPEL HILL - Three infusions of your own stem cells - each infusion over a 21-day hospitalization - can seem daunting. But, when it's your best chance for beating a recurrence of testicular cancer, you look forward to it."It doesn't seem intimidating to me at all," said David Alston, 42, of Carrboro. "You don't normally think of stem cell bone marrow transplants as treatment for testicular cancer, but it has been done in New York with success. I'm pleased it's available to me here at UNC Hospitals."This month Alston is having the first triple-tandem transplant done in an adult at UNC Hospitals.The process involves harvesting and freezing his own stem cells, receiving high-dose chemotherapy to attack the cancer, then having the stem cells infused over three back-to-back hospitalizations."He's young and otherwise healthy, and we think this is the right thing for him," said Dr. Paul M. Armistead, assistant professor of medicine in the Division of Hematology/Oncology, a member of the UNC Lineberger Comprehensive Cancer Center and leader of Alston's transplant team. "This is his best chance for being cured."Alston, a Charlotte native, was diagnosed with aggressive testicular cancer in March 2011 after experiencing an "avalanche of symptoms.""I didn't have a lump, but I had some weird back pain and loss of feeling in one leg," David said. "By the time I had some scans, we found lymph node involvement in a lot of places. Essentially, the cancer had gone on vacation all over my body."Testicular cancer is one of the more curable cancers, often cured in the first round of chemotherapy, said Dr. Kim Rathmell, associate professor of medicine, a member of UNC Lineberger Comprehensive Cancer Center and Alston's medical oncologist.Aggressive chemotherapy sent the cancer into remission, and by August Alston returned to his long-time job at Weaver Street Market in Chapel Hill's Southern Village.Routine blood test results in December surprised everyone: the cancer was back."Because of the way David's cancer came back, a more aggressive approach than chemotherapy alone was needed," said Rathmell, adding how hard it was knowing Alston faced treatment again. "I shop that store, and I had seen him back at work."Dr. Matthew Milowsky, who participated in the development of the triple-tandem transplant for testicular cancer at Memorial Sloan Kettering in New York City, joined UNC Lineberger Comprehensive Cancer Center last fall as co-director of UNC's urologic oncology program. Rathmell quickly recruited him to Alston's team."We have everything we need here at UNC to treat David," Rathmell said. "Had David come to us five years ago, when this recommended treatment was newer and we didn't have local expertise, I would likely have referred him elsewhere. Today, we are very comfortable doing this transplant here. And it's a total team approach."In January, Alston began receiving two types of chemotherapy to mobilize his stem cells in preparation for collection.This chemotherapy featured one less drug than what he endured after initial diagnosis and yielded fewer side effects."It was night and day difference," he said, remembering the physical and mental side effects that sent him into the ICU last spring. "By comparison, what I'm doing in preparation for the transplant has been rather effortless."But the process is complicated and has many moving parts."David will have five chemotherapy infusions administered by two separate medical teams that have to work together through a lot of logistics about what happens when," said Armistead. "That David is organized and intelligent and sends a lot of questions to Dr. Rathmell and me via email, he's helping himself stay on top of things. Having a patient who is fully aware of what's going on has kept us on our toes and helped us develop and coordinate a more fool-proof system."Still, as a single, stubbornly independent man, Alston needed help and support. Luckily, his mother, Barbara Alston, a retired medical professional from Concord, is by his side.Both are staying at SECU Family House, the 40-bedroom hospital hospitality house minutes from UNC Hospitals for seriously ill adult patients and their family member caregivers.The Alstons will stay at Family House during the nine weeks total that David is expected to be hospitalized. He will join her between transplants and for post-transplant monitoring."It's a comfort being here at Family House," Barbara Alston said. "If we need something, it's taken care of, both here and at the hospital. I'm assured David's getting the care he needs. I'm helping him whenever and wherever I can."SECU Family House will play an even larger role in Alston's recovery post-transplant, both Rathmell and Armistead agreed."This treatment is intense, and David will be more in the hospital than out," Rathmell said. "He will need a solid support system, and he has that with his mother. It's a fragile time, and she has his best interest at heart.""Post-transplant David will need to be monitored closely because his immune system will be very weak," Armistead said. "His mother's medical background is a bonus. The Family House folks are used to immune-suppressed patients and can get them to the hospital quickly if needed."Alston has kept himself swimming in information to minimize the fear and mystery. Barbara has been the great translator when his own efforts didn't yield the level of detail he needed."The constant learning gives it all a degree of routine that took some of the scariness away," Alston said. "But you can't be too independent or too brainy when you have cancer."Cancer blows you out of the water, but it leaves you with valuable insight," he said. "How you deal with cancer is self-guided and you learn things about yourself and your personality that you never knew. It's the ultimate in snatching the silver lining from a cloud."

Elizabeth Swaringen wrote this article for UNC Health Care.

View post:
Carrboro man to get stem cell transplant

Posted in Stem Cells | Comments Off on Carrboro man to get stem cell transplant

Cancer Stem Cell Research Drives Growth in RBCC’s Target Market

Posted: February 22, 2012 at 7:51 pm

NOKOMIS, Fla.--(BUSINESS WIRE)--

Research into Cancer Stem Cells (CSC) is on the rise, fueling industry growth that Rainbow Coral Corp. (OTCBB: RBCC.OB - News) expects to translate into demand for n3D cell growth technologies.

RBCC is finalizing an equity funding agreement with n3D Biosciences, the maker of a revolutionary new system that allows scientists to grow three-dimensional cell cultures more easily than ever before. The device, called the Bio-Assembler, could have an extraordinary impact on cell research worldwide, and RBCC expects to find a strong market for the device once its funding agreement with n3D is finalized.

Many cancers, including breast, prostate, pancreatic, colon, brain, and lung cancers, contain a subset of stem-like cells understood to play a critical role in the development and progression of the disease. Research suggests that these cells, called Cancer Stem Cells, are able to “seed” new tumor formation and drive metastasis.

Because these cells are believed to be at the root of the development and spread of cancer, they’re quickly becoming the center of cancer diagnostics and biomarkers. CSCs are resistant to a number of chemotherapy drugs and radiotherapy, and approximately 20 different strategies are currently being pursued in the hope of selectively targeting CSCs. This creates a huge opening for new companies and technologies dedicated to streamlining cellular research.

RBCC believes that the Bio-Assembler could allow researchers to dramatically shorten the development timeline for new CSC drugs and treatments, potentially proving very lucrative to the company.

For more information on Rainbow BioSciences, please visit http://www.rainbowbiosciences.com/investors.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Celgene Corp. (NASDAQ: CELG), Cardinal Health, Inc. (NYSE: CAH), Abbott Laboratories (NYSE: ABT) and Affymax, Inc. (NASDAQ: AFFY).

Follow us on Twitter at www.twitter.com/RBCCinfo.

About Rainbow BioSciences

Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.rainbowbiosciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Go here to see the original:
Cancer Stem Cell Research Drives Growth in RBCC’s Target Market

Posted in Stem Cells | Comments Off on Cancer Stem Cell Research Drives Growth in RBCC’s Target Market

Page 2,850«..1020..2,8492,8502,8512,852..2,8602,870..»